行情

ADMA

ADMA

Adma生物制品
NASDAQ

实时行情|Nasdaq Last Sale

4.255
+0.185
+4.55%
交易中 14:23 11/19 EST
开盘
4.090
昨收
4.070
最高
4.280
最低
4.060
成交量
41.79万
成交额
--
52周最高
6.31
52周最低
2.080
市值
1.93亿
市盈率(TTM)
-3.8097
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADMA 新闻

  • 分析师:iPhone 11需求强劲 获得“巨大”成功
  • 新浪财经.19分钟前
  • 无论谁赢得下月大选 英国将卷入新一波债务洪流
  • 新浪美股.22分钟前
  • 美国科技巨头反击美国议员反垄断担忧 回应来了
  • 新浪美股.32分钟前
  • 麻烦不断!电子烟巨头Juul因针对青少年推销再遭起诉
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
+2.08%
制药与医学研究
+0.71%

热门股票

名称
价格
涨跌幅

ADMA 简况

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
展开

Webull提供ADMA Biologics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。